First day of trading in Polymer Factory’s shares and warrants at Spotlight Stock Market
Today is the first day of trading in Polymer Factory Sweden AB’s (“Polymer Factory” or the “Company”) shares and warrants. Polymer Factory’s shares are traded under the ticker “POLYMER” with ISIN SE0015244470 and the Company’s warrants are traded under the ticker “POLYMER TO 1” with ISIN SE0015557293.
Prior to listing at Spotlight Stock Market, Polymer Factory conducted a successful IPO which was subscribed to a total of approx. 687 percent (incl. pre-subscription) and provided the Company with initially approx. SEK 13 million (before issue costs).
The number of shares in Polymer Factory amounts to 6,859,198 and the share capital is SEK 685,919.80. In addition, there are a total of 568,066 outstanding warrants of series TO 1. The exercise period of the warrants is planned to take place between February 24, 2022 – March 17, 2022. Each warrant entitles the holder to subscribe for one new share in the Company at a price of SEK 9.10 per share. Upon full exercise of all attached warrants, Polymer Factory will receive approx. SEK 5.2 million before issue costs.
Advisors
Polymer Factory has in connection with the issue of units appointed Sedermera Fondkommission as financial advisor, Markets & Corporate Law Nordic AB as the legal advisor, and Nordic Issuing as issuing agent.
For additional information regarding the capitalization, please contact:
Sedermera Fondkommission
Phone: +46 (0) 40-615 14 10
E-mail: info@sedermera.se
For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com
This information is information that Polymer Factory is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on April 7, 2021.
Polymer Factory is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.